eCommons@AKU
Department of Pathology and Laboratory
Medicine

Medical College, Pakistan

1-6-2022

Distribution of serotypes and antibiotic resistance of invasive
Pseudomonas aeruginosa in a multi-country collection
Shamima Nasrin
University of Maryland School of Medicine

Nicolas Hegerle
University of Maryland School of Medicine

Shaichi Sen
University of Maryland School of Medicine

Joseph Nkeze
University of Maryland School of Medicine

Sunil Sen
University of Maryland School of Medicine

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol
Part of the Bacteria Commons, Immunology and Infectious Disease Commons, Laboratory and Basic
Science Research Commons, Microbiology Commons, and the Pathology Commons

Recommended Citation
Nasrin, S., Hegerle, N., Sen, S., Nkeze, J., Sen, S., Permala-Booth, J., Choi, M., Sinclair, J., Tapia, M. D.,
Shakoor, S. (2022). Distribution of serotypes and antibiotic resistance of invasive Pseudomonas
aeruginosa in a multi-country collection. BMC microbiology, 22(13).
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1377

Authors
Shamima Nasrin, Nicolas Hegerle, Shaichi Sen, Joseph Nkeze, Sunil Sen, Jasnehta Permala-Booth,
Myeongjin Choi, James Sinclair, Milagritos D. Tapia, and Sadia Shakoor

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1377

(2022) 22:13
Nasrin et al. BMC Microbiology
https://doi.org/10.1186/s12866-021-02427-4

Open Access

RESEARCH

Distribution of serotypes and antibiotic
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Jan Jacobs21,22, Octavie Lunguya23,24, Raphael Simon1,2, Alan S. Cross1,2† and Sharon M. Tennant1,2*†

Abstract
Background: Pseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic
infections and is frequently associated with healthcare-associated infections. Because of its ability to rapidly acquire
resistance to antibiotics, P. aeruginosa infections are difficult to treat. Alternative strategies, such as a vaccine, are
needed to prevent infections. We collected a total of 413 P. aeruginosa isolates from the blood and cerebrospinal fluid
of patients from 10 countries located on 4 continents during 2005–2017 and characterized these isolates to inform
vaccine development efforts. We determined the diversity and distribution of O antigen and flagellin types and
antibiotic susceptibility of the invasive P. aeruginosa. We used an antibody-based agglutination assay and PCR for O
antigen typing and PCR for flagellin typing. We determined antibiotic susceptibility using the Kirby-Bauer disk diffu‑
sion method.
Results: Of the 413 isolates, 314 (95%) were typed by an antibody-based agglutination assay or PCR (n = 99). Among
the 20 serotypes of P. aeruginosa, the most common serotypes were O1, O2, O3, O4, O5, O6, O8, O9, O10 and O11; a
vaccine that targets these 10 serotypes would confer protection against more than 80% of invasive P. aeruginosa infec‑
tions. The most common flagellin type among 386 isolates was FlaB (41%). Resistance to aztreonam (56%) was most
common, followed by levofloxacin (42%). We also found that 22% of strains were non-susceptible to meropenem and
piperacillin-tazobactam. Ninety-nine (27%) of our collected isolates were resistant to multiple antibiotics. Isolates with
FlaA2 flagellin were more commonly multidrug resistant (p = 0.04).
Conclusions: Vaccines targeting common O antigens and two flagellin antigens, FlaB and FlaA2, would offer an
excellent strategy to prevent P. aeruginosa invasive infections.
Keywords: Pseudomonas, Serotype, Flagellin, Multidrug resistance
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Background
Pseudomonas aeruginosa is an opportunistic human
pathogen that causes acute life-threatening infections in
elderly, critically ill and immunocompromised patients
worldwide [1]. P. aeruginosa is a common cause of
healthcare-associated infections (HAIs). Magill et al. [2]
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reported a point prevalence study in the United States
which determined that P. aeruginosa was responsible for
7.1% of HAIs. This finding is supported by recent data
from the National Healthcare Safety Network (NHSN)
from 2015 to 2017 which reported P. aeruginosa as the
fourth (8%) most frequently isolated pathogen in all HAIs
in the U.S. [3]. Likewise, in the European Union, Walter
et al. [4] performed a point prevalence study to investigate healthcare-associated pneumonia and determined
that P. aeruginosa was the most commonly isolated
pathogen (17%). This bacterium also causes chronic pulmonary infections in chronic wounds and cystic fibrosis
(CF) patients [5, 6].
Severe life-threatening infections caused by P. aeruginosa are difficult to treat because of the organism’s limited susceptibility to antimicrobial agents [7]. Multi-drug
resistant (MDR) P. aeruginosa is a serious concern for
hospitalized patients. The SENTRY antimicrobial surveillance program, which collects data from 400 medical
centers worldwide, showed that most of the P. aeruginosa isolates were from patients with pneumonia followed by bloodstream infections during 1997–2016 [8].
The SENTRY surveillance program also reported that
27.7 and 23.7% of P. aeruginosa from pneumonia and
bloodstream infections, respectively, were MDR [8].
MDR isolates were most frequently isolated from Latin
America followed by Europe, North America and AsiaPacific. Unfortunately, no sites from Africa are included
in the SENTRY program. The emergence of antibiotic
resistance significantly limits therapeutic options for this
bacterium.
O-polysaccharide (OPS), the most variable region of
lipopolysaccharide (LPS), plays an important role in virulence and is responsible for conferring serogroup specificity [9]. Several serotyping systems have been proposed
by various investigators; however, the most common
serotyping scheme is the International Antigenic Typing Scheme (IATS). According to the IATS, P. aeruginosa
have been classified into 20 different serotypes (O1 to
O20) based on the structure of their O-polysaccharide
[10, 11].
Studies have shown that isolates belonging to serotypes O1, O6, O11, and O12 account for > 65% of the P.
aeruginosa infections [12, 13] and serotype O4 and O12
isolates are more frequently associated with resistance
to various classes of antibiotics [14, 15]. Serotyping data
indicates that P. aeruginosa isolates of serotypes O5, O6
and O11 are prevalent in burn wound infections [16] and
O6 and O11 are the most prevalent serotypes in pneumonia [17, 18]. A study conducted at a Canadian hospital in 1992–1993 has found that O1, O3, O5, O6, O10,
and O11 were the most frequently identified serotypes
isolated from pus, urine, sputa and other sources [19].
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Recently, in silico serotyping of > 1000 genomes of P. aeruginosa strains using whole genome sequencing revealed
that 70% of the isolates were O3, O6, O11 or O12 [20].
Donta et al. [21] reported that serotypes O1, O2/O5, O3,
O4, O6, O7, O10 and O16, represent 90% of bacteremic
P. aeruginosa strains. Data describing the distribution of
O serotypes among invasive P. aeruginosa from diverse
geographical locations is lacking.
A study conducted by Lu et al. [17] showed a relationship between clinical outcome of pneumonia and P.
aeruginosa serotypes. Serotype O1 was associated with
mortality and serotypes O6 and O11 were prevalent in
critically ill patients [17]. Previous studies also showed
that some serotypes are more virulent than others; for
instance, serotype O11 clinical isolates were found to
secrete exotoxin U (ExoU), a toxin of the Type III Secretion System, more frequently than other serotypes [18]
and in a murine model of pneumonia, serotype O11 was
associated with increased lung injury [22].
The flagellum of P. aeruginosa consists of a polymer of
flagellin (Fla) protein encoded by the fliC gene of serotype
A (including sub-type A1 and A2) or B. There is no evidence of switching between serotype A and type B flagellin for any particular P. aeruginosa strain [23]. Antibodies
to the flagellin of P. aeruginosa are protective which has
been documented in pre-clinical models of subcutaneous
infections, burn wounds and pneumonia [24]. It is not
known whether there is a relationship between strains of
particular flagellin types and antimicrobial susceptibility.
To control the spread of P. aeruginosa infection, an
effective vaccine or other alternative immunotherapy is
urgently needed. Despite decades-long efforts by the scientific community, no vaccine has yet been licensed to
prevent infections by this pathogen [25]. Several groups
have developed vaccines to prevent P. aeruginosa infections by targeting lipopolysaccharide (LPS), flagella,
alginate, outer membrane proteins (OMPs) and proteins of the Type III Secretion System (T3SS) [26–31]. A
double-blind randomized Phase 3 trial in cystic fibrosis
patients with a bivalent P. aeruginosa A/B flagellin vaccine revealed robust and durable antibody titers, and
modest but statistically significant protection against
P. aeruginosa infection in cystic fibrosis patients [32].
Unfortunately, the company that manufactured this vaccine stopped production and it is not currently available,
but these data establish the proof of concept that flagellin-based vaccines are efficacious. High molecular weight
OPS have been used to develop a polysaccharide-based
vaccine against P. aeruginosa [33]. We have extended this
approach and created a vaccine using the novel Multiple
Antigen Presenting System (MAPS) to target 8 P. aeruginosa O-serotypes (O1, O2, O3, O4, O5, O6, O10 and
O11) [34].
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In this study, we examined the diversity of O-antigen
serotypes and flagellin types among invasive P. aeruginosa isolates to get better insight into globally circulating
serotypes and their antibiotic susceptibility. The findings
from the present study provide information about the
global serotype distribution of this pathogen which will
facilitate development of an effective vaccine against P.
aeruginosa.

Results
Antibiotic resistance

In this study, we collected 413 invasive clinical isolates
of P. aeruginosa from patients’ blood and cerebrospinal
fluid from 10 countries (Table 1). Antibiotic susceptibility
was determined for 370 P. aeruginosa invasive isolates by
the disk diffusion method. Isolates obtained from Greece
were excluded from all analyses involved in antimicrobial resistance because they were part of an MDR collection (Supplementary Fig. S1 and Fig. S2). Invasive P.
aeruginosa strains were most frequently resistant to the
antibiotic aztreonam (56%), followed by levofloxacin 42%
(Table 2). We found 22% of strains were non-susceptible
to carbapenems. The distribution of MDR P. aeruginosa
varied by country. No MDR P. aeruginosa isolates were
identified in Mali.
Serotyping and global distribution of invasive P.
aeruginosa

All 413 P. aeruginosa invasive isolates were serotyped
using a commercially available antibody-based serotyping kit (Supplementary Fig. S1). The distribution of
serotypes is shown in Fig. 1A. The most prevalent serotypes were O11 (n = 89; 22%), O1 (n = 58; 14%) and O6
(n = 53; 13%) which accounted for around 50% of the
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P. aeruginosa strains that are circulating worldwide.
Ninety-nine isolates (24%) were non-typable using the
commercially available antibody-based serotyping kit.
To serotype these non-typable isolates (n = 99), we used
an O-antigen specific PCR (Fig. 1B). Unlike the antibody-based agglutination assay which can serotype P.
aeruginosa strains into 17 O types, PCR can categorize
isolates into 11 groups of gene clusters that are highly
divergent from one another at the DNA sequence level
[35]. The most prevalent serotype identified using PCR
was O6 followed by the O2/O5/O16/O18/O20 cluster
which comprised 9 and 6% of the isolates, respectively.
We were able to serotype 95% (n = 393) of the P. aeruginosa isolates using both antibody-based agglutination and PCR methods. Only 5% (n = 20) of the isolates
remained non-typable after employing both serotyping
methods. We randomly selected 8 isolates that did not
agglutinate with typing antibodies but were identified
as O1, O2/O5/O16/O18/O20, O3/O15 or O6 strains by
PCR and showed that they were able to produce O-side
chains of the LPS (Supplementary Fig. S3). We have
determined the serotype of 95% of the P. aeruginosa
isolates using agglutination and PCR methods (Fig. 1C).
Taken together, we found that the most common O
serotypes amongst 413 strains include O1, O2/O5/
O16/O18/O20, O3/O15, O6, O7/O8, O9, O10/O19 and
O11/O17 which represented 92% of the isolates.
We also determined the global serotype distribution of P. aeruginosa isolates among different countries using the agglutination data (Fig. 2). Overall, we
observed diverse serotypes of invasive P. aeruginosa
circulating worldwide. Clinically important O1, O6
and O11 serotypes were generally the most common in
each country.

Table 1 Source and origin of Pseudomonas aeruginosa isolates used in this study
Region

Country

North America

USA

Europe

Africa

Asia

a

Institute of isolation

Source

Years of isolation

No. of strains

University of Maryland, Medical Center

Blood

2010 to 2015

116

Duke University Medical Center

Blood

2012 to 2015

51

Sweden

Karolinska University Hospital

Blood

2015

25

Greece

AHEPA University Hospital

Blood

2012 to 2016

43

Denmark

Statens Serum Institute

Blood

2017

35

South Africa

NICDa South Africa

Blood

2015

50

Mali

CVDb-Mali

Blood/CSF

2005 to 2012

24

DR Congo

ITMc Belgium

Blood

2015

3

Japan

Nagoya University Hospital

Blood

2010 and 2015

14

Singapore

Singapore General Hospital

Blood

2012 to 2016

25

Pakistan

Aga Khan University

Blood

2015 to 2017

27

National Institute for Communicable Diseases

b

Center for Vaccine Development and Global Health

c

Institute of Tropical Medicine, Antwerp
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Table 2 Antibiotic resistance of invasive P. aeruginosa
Countrya

No. of
isolates

No. of isolates (%) non-susceptible to

MDR

Aminoglycoside

Carbapenem

Cephalosporin

Fluoroquinolone

β-lactamase
inhibitor

Monobactam

Amikacin Gentamicin

Meropenem

Cefepime

Levofloxacin

Piperacillintazobactam

Aztreonam

USAb

116

0 (0)

10 (8.6)

23 (19.8)

10 (8.6)

48 (41.4)

24 (21.0)

56 (48.3)

USAc

51

0 (0)

7 (14.0)

9 (17.6)

5 (10.0)

21 (41.2)

13 (25.5)

27 (53.0)

14 (27.4)

Denmark

35

2 (5.7)

2 (5.7)

6 (17.1)

5 (14.3)

20 (57.1)

5 (14.3)

27 (77.1)

8 (22.8)

28 (24.1)

Sweden

25

2 (8.0)

2 (8.0)

4 (16.0)

2 (8.0)

9 (36.0)

3 (12.0)

6 (24.0)

5 (20.0)

South
Africa

50

8 (16.0)

15 (30.0)

18 (36.0)

17 (34.0)

25 (50.0)

15 (30.0)

42 (84.0)

20 (40.0)

Mali

24

1 (4.2)

1 (4.2)

0 (0)

0 (0)

1 (4.2)

0 (0)

8 (33.3)

0 (0)

DR Congo

3

0 (0)

2 (66.7)

1 (33.3)

1 (33.3)

2 (66.7)

2 (66.7)

2 (66.7)

2 (66.7)

Japan

14

0 (0)

0 (0)

4 (28.6)

0 (0)

4 (28.6)

0 (0)

7 (50.0)

2 (14.3)

Singapore

25

2 (8.0)

7 (28.0)

9 (36.0)

9 (36.0)

12 (48.0)

10 (40.0)

16 (64.0)

11 (44.0)

Pakistan

27

6 (22.2)

6 (22.2)

8 (29.6)

8 (29.6)

14 (51.8)

9 (33.3)

15 (55.5)

9 (33.3)

Overall

370

21 (5.7)

52 (14.0)

82 (22.2)

57 (15.4)

156 (42.2)

81 (22.0)

206 (55.7)

99 (26.7)

a

Isolates collected from Greece were excluded

b

Isolates were obtained from University of Maryland Medical Center

c

Isolates were obtained from Duke University Medical Center

Flagellin typing of P. aeruginosa

The most common flagellin type among 386 (flagellin typing was not performed on 27 isolates due to
logistic constraints) invasive P. aeruginosa isolates was
FlaB (41%), followed by FlaA2 (31%) and FlaA1 (28%)
(Fig. 3A). No PCR product was observed for three strains
(one from Singapore which was not motile and two from
Pakistan which were motile). We found that FlaB was
prevalent in isolates from South Africa (58%), Pakistan
(52%) and Greece (51%) whereas isolates from Denmark
and Sweden were predominantly FlaA2 (49%) and FlaA1
(48%) (Fig. 3B). Overall, we observed diverse profiles of
flagellin types among different countries. We observed a
significant association between O serotypes and flagellin
type (Chi-squared test, p < 0.001) where strains that possess FlaA1 were likely to be associated with serotype O6
(38.3%) and FlaA2 isolates were likely to be serotype O11
(42.4%) or O1 (22.9%) (Fig. 3C). Isolates with FlaB were
likely to be associated with serotype O11 (15.9%) and
O3 (14.6%). Furthermore, non-typable O serotypes were
associated with FlaA1 and FlaB.
To determine if particular flagellar types were associated with antibiotic resistance, we evaluated the distribution of flagellar types among susceptible and
non-susceptible strains for each antibiotic and for MDR
and non-MDR strains. We observed that FlaA2 was significantly (p < 0.05) associated with MDR. In contrast,
FlaB was more common amongst non-MDR than MDR
strains (p < 0.05) (Fig. 4A). The percentage of flagellar

types in susceptible and non-susceptible groups to each
antibiotic is shown in Fig. 4B. We found significantly
more FlaA2 isolates that were non-susceptible to gentamicin, levofloxacin, piperacillin-tazobactam and aztreonam compared to susceptible (p < 0.05). In contrast,
FlaB type was significantly more common in isolates
susceptible to meropenem, cefepime, levofloxacin and
piperacillin-tazobactam. We did not find any significant
difference in FlaA1 distribution in susceptible versus
non-susceptible strains.

Discussion
In this study, we collected more than 400 invasive P. aeruginosa isolates from geographically diverse locations to
determine their serotype distribution, flagellin types and
antibiotic susceptibility pattern to understand the epidemiology of this pathogen and to guide vaccine development efforts. The challenges for developing an effective
vaccine against P. aeruginosa are multifactorial, interplaying between the pathogen’s virulence factors, ability
to utilize multiple pathways to cause infection, antibiotic
resistance, emerging high-risk clones and host factors
[36]. Emergence of MDR P. aeruginosa is a serious public
health concern.
We observed that 26.7% of the P. aeruginosa isolates
tested (N = 370) were MDR. Our data are similar to
those of the SENTRY surveillance program which found
23.7% MDR out of 52,022 P. aeruginosa isolates collected
in 1997–2016 from > 400 medical centers representing
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Fig. 1 Distribution of O serotypes in 413 invasive P. aeruginosa isolates. A O serotypes were determined by slide agglutination assay. B Isolates that
were non-typable (NT) by the slide agglutination assay were O-typed by PCR (n = 99). C Distribution of O serotypes using slide agglutination and
PCR assays for O-antigen typing. mAb’s, monoclonal antibodies
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Fig. 2 Diversity of P. aeruginosa O serotypes by country using an antibody based serotyping kit. The numbers on top of the graph represent the
number of isolates tested from each country

Asia-Pacific, Europe, Latin America and North America
[8]. We found the highest prevalence of MDR isolates
from Singapore, South Africa and Democratic Republic of the Congo (albeit only 3 isolates of the latter were
tested).
Cefepime is a widely used fourth generation cephalosporin that has potent antimicrobial activity against
Pseudomonas [37]. However, resistance of P. aeruginosa
to cefepime has been observed in several other studies [37–39] as well as in this study. This observation of
resistance to cefepime is of concern as Akhabue et al.
[38] showed a significant association between infections
caused by invasive cefepime-resistant P. aeruginosa and
increased mortality among hospitalized patients.
In our study, 22% of the P. aeruginosa were resistant
to meropenem, an antibiotic that has been considered
as the most effective agent for the treatment of P. aeruginosa infections [40]. Our observations are similar
to that of the SENTRY surveillance program which
reported that 22.3% of bloodstream isolates were resistant to meropenem [8]. In contrast, other studies have
reported higher resistance to carbapenems; among
2070 P. aeruginosa isolates from 27 hospitals located in
14 European and Mediterranean countries, 94.5% were
resistant to imipenem, 81.6% to meropenem and 57.3%
to doripenem using Clinical and Laboratory Standards
Institute (CLSI) breakpoints [41]. The increased prevalence of carbapenem resistance among the 2070 P. aeruginosa isolates reported by Castanheira et al. might
be due to the varied source of the isolates which were
obtained from bloodstream, nosocomial respiratory
tract infections, skin, urine and other unknown sources
(in contrast to our study where isolates were obtained

from blood or cerebrospinal fluid). It is worth noting
that the World Health Organization (WHO) recently
ranked carbapenem-resistant P. aeruginosa as critical
in their global priority pathogens list of MDR bacteria
to help in prioritizing the research and development of
new and effective antibiotic treatments [42].
One of the objectives of this study was to identify the
most common serotypes of P. aeruginosa circulating to
inform development of O-polysaccharide-based vaccines. We found that the distribution of serotypes varied amongst investigation sites and countries, but the
most prevalent serotypes were O1, O6 and O11, which
comprise about 50% of tested isolates. These results are
concordant with findings from previous studies [13].
To our knowledge, this is the first study to evaluate
the distribution of P. aeruginosa serotypes in invasive
infections from multiple (ten) countries with diverse
geographical locations. Our antibody-based serotyping data indicated that > 70% of the isolates belonged
to 10 serotypes (O1, O2, O3, O4, O5, O6, O8, O9, O10
and O11). However, antibody-based serotyping data in
combination with the molecular method, determined
that > 80% of the strains belonged to these 10 serotypes.
Thus, targeting these 10 serotypes in a vaccine could
conceivably confer protection against infection caused
by a large number of invasive P. aeruginosa strains. We
and others have observed a low prevalence of serotype
O12 in clinical strains [13, 18]; however, other studies have shown that isolates of serotype O12 are more
frequently associated with antibiotic resistance [14].
Therefore, serotype O12 might be included in future
vaccine programs to prevent spread of antimicrobial
resistant strains.
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Fig. 3 Distribution of flagellin types. A Distribution of flagellin types amongst 386 invasive P. aeruginosa isolates by PCR. The numbers on top of
the graph represent the number of isolates of each flagellin type. B Distribution of flagellin types by country. The numbers on top of the graph
represent the number of isolates tested from each country. C Distribution of O serotypes by flagellin type
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Fig. 4 Association between flagellin types and antibiotic resistance in clinical P. aeruginosa strains. A Inner circle of the pie represents the
percentage of flagellin types that are non-MDR and the outer circle of the pie represents the percentage of flagellin types that are MDR. B The
percentage of flagellin types in susceptible isolates (inner circle) and in non-susceptible isolates (outer circle) to each antibiotic. Statistically
significant differences between MDR and non-MDR and susceptible and non-susceptible groups are indicated by asterisks (*). Isolates obtained
from Greece were excluded from the analysis

In the current study, the most common flagellin type
was FlaB (40.6%) followed by FlaA2 (30.8%) and FlaA1
(27.7%) and distribution of flagellin types among countries was diverse. We found that strains with FlaA1 were
significantly associated with O6 and O11; FlaA2 strains
were frequently serotyped as O1 or O11; and isolates that
possessed FlaB were significantly associated with O11
and O3. We also observed that FlaA2 was the predominant flagellin type among MDR P. aeruginosa strains and

was associated with resistance to gentamicin, levofloxacin, piperacillin-tazobactam and aztreonam. The role of
flagella or flagellin proteins in virulence of P. aeruginosa
have been previously documented [43]; however, to our
knowledge, no association between flagellin type and
antibiotic resistance has been described for P. aeruginosa.
Given the conserved nature and limited flagellin types in
P. aeruginosa, it would be worthwhile to include flagellin proteins as a vaccine component to improve vaccine
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coverage. Our data suggests that although FlaB was the
most common flagellin type, it would also be important
to target FlaA2 strains which are associated with antibiotic resistance.

Conclusions
We determined antibiotic susceptibility of invasive P.
aeruginosa collected from 10 countries located on 4 different continents. The distribution of MDR P. aeruginosa
varied by country. P. aeruginosa strains were most frequently resistant to the antibiotic aztreonam, followed by
levofloxacin and 22% of the invasive isolates were nonsusceptible to carbapenems. Our data suggest that a multivalent vaccine that targets 10 O serotypes (O1, O2, O3,
O4, O5, O6, O8, O9, O10 and O11) would confer protection against > 80% of circulating invasive P. aeruginosa
isolates. We also determined that if one was to include
flagellin antigens in a vaccine, it would be important to
include FlaB (most common flagellin type) and FlaA2
(associated with antibiotic resistance). The findings from
this study will help to guide efforts to develop an effective
vaccine against invasive P. aeruginosa.
Materials and methods
Bacterial isolates collection and growth conditions

Four hundred and thirteen invasive clinical isolates of P.
aeruginosa were collected during 2005–2017 from ten
countries located in four different geographic regions
(Table 1). Bacterial isolates were collected from patients’
blood and cerebrospinal fluid. As reference strains, the
International Antigenic Typing Scheme (IATS) serotypetype specific strains, IATS O1, O2, O3, O4, O5, O6, O7,
O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, were
used. P. aeruginosa was isolated and identified at each site
using standard microbiologic protocols. As needed, identity was confirmed by morphological characteristics and
biochemical profile using API 20NE (bioMérieux, Durham, NC) at the Center for Vaccine Development and
Global Health (CVD), University of Maryland, Baltimore,
Maryland. All confirmed P. aeruginosa isolates were preserved in Tryptic Soy Broth (TSB) supplemented with
15% (vol/vol) glycerol and stored at − 80 °C for future use.
When needed, bacteria were streaked for single colonies
on animal product-free Hy-Soy agar plates (0.5% sodium
chloride, 1% animal free soytone [TEKNova, Hollister,
CA], 0.5% Hy-Yest 444 [Kerry Biosciences, Beloit, WI]).
For routine culture, cells were incubated at 37 °C for
18–24 h unless otherwise indicated. For motility tests,
bacteria were stab inoculated using a sterile pipette tip
onto a motility medium containing 1% tryptone, 0.5%
NaCl, and 0.4% agar and the plates were incubated for
18 h at 37 °C.
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Antibiotic susceptibility testing

Antibiotic susceptibility studies were performed by
Kirby-Bauer disk diffusion method according to CLSI
guidelines (M100-S29). The following antibiotics were
tested in this study: amikacin (30 μg), aztreonam (30 μg),
cefepime (30 μg), gentamicin (10 μg), meropenem (10 μg),
piperacillin-tazobactam (110 μg) and levofloxacin (5 μg).
Cartridges of antibiotic impregnated discs were purchased from Becton Dickinson Company Ltd. (Franklin
Lakes, NJ). Antibiotic susceptibility was determined by
measuring the diameter of the zone of inhibition and
the results were interpreted as susceptible (S), intermediate (I) and resistant (R) based on CLSI guidelines [44].
The criterion used in this study for defining multidrugresistant (MDR) in P. aeruginosa was defined as nonsusceptibility (including both resistant and intermediate)
to three or more classes of antibiotics [45]. In this study,
non-MDR isolates were defined as those susceptible to all
antibiotics or resistant to 1 or 2 classes of antibiotics.
O‑antigen serotyping

P. aeruginosa isolates were serotyped by slide agglutination using commercially available antibodies specific to
P. aeruginosa (MediMabs, Montreal, Canada) according
to the manufacturer’s instructions. Briefly, P. aeruginosa
was streaked onto Hy-Soy agar medium and incubated
for 16–18 h at 37 °C. After incubation, cells were serotyped using three groups of pooled antisera (pool A, pool
B and pool C) followed by a panel of 17 monovalent antisera (O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, O11,
O12, O13, O14, O15, O16 and O17) based on the IATS
serotyping system. Cells producing clear aggregation and
clumping in the presence of antibody were considered as
serotype-positive, whereas cells that remained uniformly
suspended were considered as serotype-negative.
Isolates which were non-typable by slide agglutination
assay were O-serotyped by PCR according to a method
described previously [35]. Genomic DNA was extracted
from each of the non-typable isolates using the GenElute genomic DNA purification kit (Sigma-Aldrich, Billerica, MA) according to the manufacturer’s instructions.
O-antigen specific PCR was performed as follows: each
25 μl reaction mixture contained 2.5 μl of 10× Greentaq buffer (Genscript, Piscataway, NJ), 0.5 μl of 10 μM
deoxynucleotide triphosphate mix (dNTPs) (Genscript),
1.0 μl of 10 μM forward and reverse primer mix (See
Table S1 for details of primers), 0.5 U of Greentaq DNA
polymerase (Genscript) and 40 ng of DNA template.
Cycling parameters were 95 °C for 3 min followed by
35 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 45 s
to 1.5 min (depending on the primer mixes) with a final
extension at 72 °C for 5 min. PCR amplicons (10 μl) were
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electrophoresed on 1.0% agarose gels and photographed
using a ChemiDoc™ MP imaging system (Bio-Rad, Hercules, CA). O-serotype was determined based on the
presence or absence of an amplicon.
Lipopolysaccharide (LPS) extraction

Eight representative non-typable P. aeruginosa isolates
were selected to confirm expression of O polysaccharide.
Crude LPS was extracted from P. aeruginosa isolates,
electrophoresed and visualized by staining. P. aeruginosa strain PAK was used as a positive control. Cells were
grown overnight in 3 ml of Hy-Soy broth in a shaking
incubator at 37 °C and 200 rpm. After incubation, cells
were pelleted by centrifugation followed by washing the
pellet twice with 1 × PBS to remove any pyocyanin from
the media (to remove pigments that can affect spectrophotometric measurements). Pellets were resuspended
in PBS and optical density (OD) at 600 nm was adjusted
to 1.0. One milliliter of the OD600 standardized culture
was centrifuged at 15,600×g for 1 min. Supernatant was
discarded carefully without disturbing the pellet. The pellet was suspended in 250 μl of Laemmli buffer 1× with
β-mercaptoethanol (BME). Samples were boiled at 100 °C
for 20 min, allowed to cool at room temperature and
then 20 μg of proteinase K (Qiagen Germantown, MD)
was added to the solution. The solution was incubated
at 55 °C for 4 h. Proteinase K was then heat inactivated at
100 °C for 10 min. For electrophoresis, 25 μl of the sample and 2 μl of CandyCane glycoprotein molecular weight
standard (Invitrogen Waltham, MA) was loaded onto
a NuPAGE 4–12% Bis-Tris Gel (Invitrogen Carlsbad,
CA) and LPS visualized using the Pro-Q® Emerald 300
lipopolysaccharide gel stain kit according to the manufacturer’s instructions (Thermo Fisher Waltham, MA).
Flagellin typing of Pseudomonas aeruginosa

To determine flagellin types for P. aeruginosa isolates,
the central region of the fliC gene was amplified by PCR
and sequenced using primer pair CW46_F (5′-GGC
CTGCAGATCNCCAA-3′) and CW45_R (5′-GGCAGC
TGGTTNGCCTG-3′) [46]. The primer pair used in this
study produced amplicons that can differentiate between
A and B type flagellin. Boiled lysates of P. aeruginosa isolates were used as DNA template for performing flagellin-specific PCR. Four to six colonies were suspended
in 150 μl of nuclease free water. Samples were boiled at
100 °C for 10 min and then pelleted by centrifugation at
14,000 rpm for 5 min. The supernatants were collected
and used as DNA template. PCR was performed as follows: each 50 μl reaction mixture contained 5.0 μl of 10×
Greentaq buffer (Genscript), 1.5 μl of 2 mM deoxynucleotide triphosphate mix (dNTPs) (Genscript), 3.0 μl
of 10.0 μM forward and reverse primer mix, 1.0 U of
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Greentaq DNA polymerase (Genscript) and 1.0 μl of
DNA template. Reactions were incubated at 95 °C for
3 min followed by 30 cycles of denaturation at 95 °C for
30 s, annealing at 56 °C for 45 s, and extension at 72 °C for
1.5 min, with a final extension at 72 °C for 5 min. The PCR
products were analyzed by agarose gel electrophoresis.
To differentiate between A1 and A2 subtypes, a new set
of primers (PA_FLIC_F: 5′-ATGGCCTTGACCGTC
AAC-3′ and PA_FLIC_R: 5′-GCGCAGCAGGCTCAG
AAC-3′) were used to generate fliC amplicons and for
sequencing. PCR was performed according to the conditions described above.
Amplicons were then purified using the Qiagen PCR
purification kit (Germantown, MD) according to the
manufacturer’s protocol. Purified PCR products were
sequenced by Genewiz (South Plainfield, NJ). Sequences
were de novo assembled and compared with reference
sequences using the Geneious software package.
Statistical analysis

The proportion of susceptible versus resistant strains for
each flagellin type was analyzed by Chi-squared analysis with Yate’s correction using GraphPad Prism version
7 software (GraphPad Software, San Diego). The significance level was p < 0.05. The association between O serotype and flagellin type was determined by Chi-squared
test using Stata/SE version 16 software.
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